SCHEMBL65059

SCHEMBL65059

C[C@@H]1COc2nc([N+](=O)[O-])cn2C1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.49
MAPT P10636 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KCNH2 Q12809 5/20 0.35
RAB9A P51151 1/20 0.35
POLB P06746 1/20 0.32
CACNA1C Q13936 1/20 0.31
SCN5A Q14524 1/20 0.31
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30
CYP2C19 P33261 1/20 0.30
PTGS1 P23219 1/20 0.30
SLC6A2 P23975 1/20 0.30
SLC6A4 P31645 1/20 0.30
SOS1 Q07889 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63296 1.00 CHRM1 (0.49) CHRM1MAPTALDH1A1KCNH2RAB9A
SCHEMBL13461150 1.00 CHRM1 (0.49) CHRM1MAPTALDH1A1KCNH2RAB9A
SCHEMBL65130 0.82 CHRM1 (0.49) CHRM1MAPTALDH1A1KCNH2RAB9A
SCHEMBL12175735 0.82 CHRM1 (0.49) CHRM1MAPTALDH1A1KCNH2RAB9A
SCHEMBL64590 0.82 CHRM1 (0.49) CHRM1MAPTALDH1A1KCNH2RAB9A
SCHEMBL3212150 0.82 CHRM1 (0.49) CHRM1MAPTALDH1A1KCNH2RAB9A
SCHEMBL3195372 0.82 CHRM1 (0.49) CHRM1MAPTALDH1A1KCNH2RAB9A
SCHEMBL13433888 0.82 CHRM1 (0.47) CHRM1MAPTALDH1A1KCNH2RAB9A
SCHEMBL1228827 0.80 CHRM1 (0.50) CHRM1ALDH1A1KCNH2POLBCACNA1C
SCHEMBL10078251 0.80 CHRM1 (0.61) CHRM1ALDH1A1KCNH2POLBCACNA1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120130082-A1 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same OTSUKA PHARMACEUTICAL CO., LTD. 2012-05-24 US disclosed
US-8129544-B2 Preparation of 4-nitroimidazoles that are 2-substituted with a halo or optionally oxidized phenylthio group and 1-substituted with hydrogen, an oxiranylmethyl-, or a phenyl- group; dehalogenation, reduction, nitration, rearrangement OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-03-06 US disclosed
US-7807843-B2 1-substituted-4-nitroimidazole compound and method for preparing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-10-05 US disclosed
US-7368579-B2 1-substituted-4-nitroimidazole compound and process for producing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20080097107-A1 1-substituted-4-nitroimidazole compound and method for preparing the same OTSUKA PHARMACEUTICAL CO. LTD. 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120130082-A1 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same CBR1, CBR3, DCXR CHRM1 286/4885MAPT 3906/4885ALDH1A1 836/4885
US-20080097107-A1 1-substituted-4-nitroimidazole compound and method for preparing the same CBR1, CBR3, DCXR CHRM1 286/4885MAPT 3906/4885ALDH1A1 836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.